



## **PRESS RELEASE**

November 12, 2024

# **Bulletin from the extraordinary general meeting of Ziccum**

**The following main resolutions were passed at the extraordinary general meeting (the "EGM") of Ziccum AB (publ) (the "Company") on 12 November 2024 in Lund.**

### **Amendment of the articles of association**

The EGM resolved, in accordance with the board of directors' proposal, to adopt new articles of association. The new articles of association contain changed limits for share capital and number of shares to enable the rights issue of units that the board of directors intends to resolve upon in accordance with the Company's press release on 10 October 2024.

### **Issue authorization**

The EGM resolved, in accordance with the board of directors' proposal, to authorize the board of directors to, during the period until the next annual general meeting and in addition to the authorization resolved upon at the annual general meeting 2024, on one or more occasions resolve on a new issue of shares and warrants. New issues of shares and warrants by virtue of the authorization may be made with or without deviation from the shareholders' pre-emption rights, against payment in cash, in kind or by way of set-off or otherwise on terms referred to in Chapter 2. Section 5, second paragraph, 1–3 and 5 of the Swedish Companies Act. Resolutions on new issues of shares and warrants by virtue of the authorization may be made with a maximum of the total number of shares and warrants that may be issued without amendment to the articles of association adopted at any time by the general meeting.

The authorization is intended to be used, among other things, to carry out the rights issue of units that the board of directors intends to resolve upon in accordance with the Company's press release on 10 October 2024, which enables the Company's continued technical development of LaminarPace® as well as further business development. The reason for why new issues of shares and warrants by virtue of the authorization may be made with deviation from the shareholders' pre-emption rights is to enable the Company to pay guarantee compensation in the form of units to guarantors who provide guarantee undertakings in the rights issue that the board of directors intends to resolve on pursuant to the authorization.

For more information about Ziccum, please contact:

---

Ann Gidner  
CEO, Ziccum AB  
Mail: gidner@ziccum.com  
Mobile: +46 722140141

Jonas Ekblom  
Chairman of the Board, Ziccum AB  
Mail: ekblom@ziccum.com  
Mobile: +46 736777540

Ziccum's Certified Adviser is  
Vator Securities AB

## About Ziccum

---

Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

## Attachments

---

[Bulletin from the extraordinary general meeting of Ziccum](#)